Biomaterials to suppress cancer stem cells and disrupt their tumoral niche
Por favor, use este identificador para citas ou ligazóns a este ítem:
http://hdl.handle.net/10347/15728
Ficheiros no ítem
Metadatos do ítem
Título: | Biomaterials to suppress cancer stem cells and disrupt their tumoral niche |
Autor/a: | Garcia-Mazas, Carla Csaba, Noemi García-Fuentes, Marcos |
Centro/Departamento: | Universidade de Santiago de Compostela. Centro de Investigación en Medicina Molecular e Enfermidades Crónicas |
Palabras chave: | Cancer stem cells | Tumor initiating cells | Tumor niche | Biomaterials | Tissue engineering | Drug delivery | Nanomedicine | |
Data: | 2017-05-25 |
Editor: | Elsevier |
Cita bibliográfica: | Garcia-Mazas, C., Csaba, N. and Garcia-Fuentes, M. (2017). Biomaterials to suppress cancer stem cells and disrupt their tumoral niche. International Journal of Pharmaceutics, 523(2), pp.490-505. Disponible en: http://dx.doi.org/10.1016/j.ijpharm.2016.12.013 |
Resumo: | Lack of improvement in the treatment options of several types of cancer can largely be attributed to the presence of a subpopulation of cancer cells with stem cell signatures and to the tumoral niche that supports and protects these cells. This review analyses the main strategies that specifically modulate or suppress cancer stem cells (CSCs) and the tumoral niche (TN), focusing on the role of biomaterials (i.e. implants, nanomedicines, etc.) in these therapies. In the case of CSCs, we discuss differentiation therapies and the disruption of critical signaling networks. For the TN, we analyze diverse strategies to modulate tumor hypervascularization and hypoxia, tumor extracellular matrix, and the inflammatory and tumor immunosuppressive environment. Due to their capacity to control drug disposition and integrate diverse functionalities, biomaterial- based therapies can provide important benefits in these strategies. We illustrate this by providing case studies where biomaterial-based therapies either show CSC suppression and TN disruption or improved delivery of major modulators of these features. Finally, we discuss the future of these technologies in the framework of these emerging therapeutic concepts |
Versión do editor: | https://doi.org/10.1016/j.ijpharm.2016.12.013 |
URI: | http://hdl.handle.net/10347/15728 |
DOI: | 10.1016/j.ijpharm.2016.12.013 |
ISSN: | 0378-5173 |
Dereitos: | © 2017 Elsevier B.V. |
Coleccións
-
- CIMUS-Artigos [249]
O ítem ten asociados os seguintes ficheiros de licenza: